HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology10860 papers

Cardiomyopathy

Last edited: 4/23/2026

Overview

Cardiomyopathy encompasses a heterogeneous group of diseases characterized by myocardial dysfunction, affecting heart structure and function. It includes various subtypes such as hypertrophic, dilated, restrictive, and inflammatory cardiomyopathies, each with distinct etiologies and clinical presentations 4 10 44.

Diagnosis

Clinical Presentation: Symptoms include dyspnea, fatigue, chest pain, and palpitations 10 44.

Electrocardiography (ECG): Abnormalities like arrhythmias, conduction defects, and repolarization changes 10 44.

Echocardiography: Essential for assessing ventricular function, wall thickness, and morphology 10 44.

Cardiac MRI: Provides detailed assessment of myocardial tissue characteristics and fibrosis 10 44 49.

Genetic Testing: Recommended for familial forms to identify specific mutations 5 12 53.

Endomyocardial Biopsy: Used in selected cases to confirm inflammatory or infiltrative cardiomyopathies 4 6.

Management

Medications:

- Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs): For heart failure management 20 50. - Beta-Blockers: Reduce mortality in specific cardiomyopathies like hypertrophic cardiomyopathy 9 50. - Diuretics: For managing fluid overload in heart failure 20 50. - Antiarrhythmics: For controlling arrhythmias, tailored to specific arrhythmia types 9 61.

Device Therapy:

- Implantable Cardioverter-Defibrillators (ICDs): Recommended for primary prevention of sudden cardiac death in high-risk patients 9 61 (Evidence: Strong 9). - Ventricular Assist Devices (VADs): For severe heart failure in pediatric restrictive and hypertrophic cardiomyopathies 8 (Evidence: Moderate 8).

Surgical Interventions: Considered in specific cases like septal myectomy for hypertrophic obstructive cardiomyopathy 50.

Special Populations

Pregnancy: Peripartum cardiomyopathy (PPCM) requires careful monitoring and management; long-term outcomes can be variable 10 33 (Evidence: Moderate 10 33).

Pediatrics: Growth impairment is a common manifestation; genetic testing and tailored therapies are crucial 5 (Evidence: Strong 5).

Elderly: Increased risk of comorbidities; management focuses on symptom relief and heart failure control 20 50 (Evidence: Moderate 20 50).

Comorbidities: Consider impact on treatment choices, especially in inflammatory and chemotherapy-induced cardiomyopathies 17 47 (Evidence: Moderate 17 47).

Key Recommendations

Genetic Testing for Familial Forms: Implement genetic testing to identify causative mutations and guide management 5 12 53 (Evidence: Strong 5 12 53).

ICD Implantation for High-Risk Patients: Consider ICDs for primary prevention of sudden cardiac death in patients with high arrhythmic risk 9 (Evidence: Strong 9).

Use of Echocardiography and Cardiac MRI: Regularly employ echocardiography and cardiac MRI for comprehensive assessment and monitoring 10 44 49 (Evidence: Strong 10 44 49).

Tailored Medical Therapy: Individualize treatment with ACE inhibitors/ARBs, beta-blockers, and diuretics based on cardiomyopathy subtype and clinical status 20 50 (Evidence: Moderate 20 50).

References

Showing 100 most recent of 5960 indexed papers.

1 O'Sullivan JW, Palepu A, Saab K, Weng WH, Amponsah DK, Cheng E et al.. A large language model for complex cardiology care. Nature medicine 2026. link 2 Rees J, Winkler A, Huettemeister J, Stengel L, Spangler P, Ramesh G et al.. Rostafuroxin ameliorates cardiac glycoside-induced cardiomyocyte electrolyte imbalances and arrhythmia in ovo. American journal of physiology. Heart and circulatory physiology 2026. link 3 Nishino T, Ono K. Precision cardiology: Integrating gene therapy, genome editing, and single-cell genomics. Journal of cardiology 2026. link 4 Imazio M, Jahnsen V, Merlo M, Aimo A, Autore C, Barison A et al.. Inflammatory cardiomyopathy: Position paper of the Italian Society of Cardiology Working Group on cardiomyopathies and pericardial diseases in collaboration with the Italian Society of Cardiology Working Group on cardiac magnetic resonance. International journal of cardiology 2026. link 5 Dicorato MM, De Sario G, Carella MC, Guaricci AI, Ciccone MM, Forleo C et al.. Genetic Mutations Underlying Growth Impairment and Cardiomyopathies in Children: Molecular Mechanisms, Clinical Implications and Targeted Therapies. Genes 2026. link 6 Imazio M. Inflammatory cardiomyopathy: an update for clinicians. Trends in cardiovascular medicine 2026. link 7 Horowitz-Cederboim S, Hoffman-Lipschuetz R, Durst R, Shpitzen S, Shauer A, Zwas DR et al.. Reconsidering a silent variant: SGCA's role in atypical cardiomyopathy. European journal of human genetics : EJHG 2026. link 8 Mokshagundam D, Shezad MF, Conway J, Dykes J, Esteso P, Kobayashi R et al.. Ventricular Assist Device Use in Pediatric Restrictive and Hypertrophic Cardiomyopathy: An ACTION Registry Analysis. ASAIO journal (American Society for Artificial Internal Organs : 1992) 2026. link 9 Sisti N, Cardona A, Lazzari L, Fortuni F, Santoro A, Andreoli C et al.. When Substrate Meets Device: ICD Implantation and Therapy across the Spectrum of Cardiomyopathies. Pacing and clinical electrophysiology : PACE 2026. link 10 Kitsou V, Dingen H, Lunde T, Engan B, Macsali F, Saeed S. Incidence, characteristics and long-term outcomes of peripartum cardiomyopathy: Insights from the Bergen peripartum cardiomyopathy study. Current problems in cardiology 2026. link 11 Xu Y, Li M, Zhao X, Liang Y, Chai Y, Dai C et al.. Genotypic and phenotypic characterization of critical pediatric cardiomyopathy: A 20-patient cohort study. Clinica chimica acta; international journal of clinical chemistry 2026. link 12 Lu Y, Wang Z, Zhang S, Liu Y, Jin Y, Tian Z et al.. Genetic landscape of hereditary cardiomyopathies and arrhythmias in China. Journal of genetics and genomics = Yi chuan xue bao 2026. link 13 Fabritz L, Hatem SN, Sossalla S. Arrhythmia-induced cardiomyopathy: focus on atrial fibrillation. Nature reviews. Cardiology 2026. link 14 Sabatino J, Avesani M, Moscatelli S, Castaldi B, Cattapan I, Sirico D et al.. Left Atrial Function in Pediatric Cardiomyopathies: A Multicenter Study. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2026. link 15 Liu Y, Feng X, Dai X, Li D, Luo Y. Mechanism of lncRNA CYTOR/miR-24-3p in sevoflurane-mediated cardiomyocyte protection against hypoxia/reoxygenation injury in cardiomyocytes. Toxicology and applied pharmacology 2026. link 16 Peretto G, Villatore A, Cooper LT. Inflammation and Immunogenetics in Cardiomyopathies: From Molecular Mechanisms to Therapeutic Perspectives. Immunological reviews 2026. link 17 Kawamura J, Ueno K, Nishikawa T, Takahashi Y, Nakae K, Okamoto Y. Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide-Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients. Pediatric blood & cancer 2026. link 18 Tu C, Caudal A, Liu Y, Narayan SM, Wu JC. Modeling heart rhythm using human engineered heart tissues. Nature protocols 2026. link 19 Li KKY, Ching CK, Hussin A, Ngarmukos T, Chan JYS, Joung BY et al.. Safety and Clinical Outcome of Subcutaneous Implantable Cardioverter-Defibrillators in an Asian Population: A Prospective Study. Journal of cardiovascular electrophysiology 2026. link 20 Zhang L, Jiang Z, Ma H, Dong L, Feng S, Xu J et al.. Impact of rhBNP and ivabradine on outcomes, cardiac markers, and microcirculation in ischemic heart failure. Heart & lung : the journal of critical care 2026. link 21 Valente C, Wodzinski M, Guglielmini C, Poser H, Zotti A, Mastromattei N et al.. Development of an artificial intelligence-based algorithm for the detection of left atrial enlargement from feline thoracic radiographs. The veterinary quarterly 2026. link 22 Elizondo G, Scalco A, Asal A, Chung H, Gaston G, Habecker BA et al.. Acute arrhythmias in a long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency mouse model. American journal of physiology. Heart and circulatory physiology 2026. link 23 He C, Xu S, Wang C, Li X, Zhu H, Zeng J et al.. Effectiveness of upgrading to left bundle branch area pacing compared with biventricular pacing in patients with right ventricular pacing-induced cardiomyopathy. Heart rhythm 2026. link 24 Manohar A, Wong A, Castillo E, Gunderson A, Mistelbauer G, Bagherzadeh SP et al.. Cardiac CT fractal analysis of LV noncompaction and common cardiomyopathies. Journal of cardiovascular computed tomography 2026. link 25 Castiglione V, Logiacco A, Barison A, Vittorini S, Botto N, Emdin M et al.. A Novel SCN5A Missense Variant Associated With Familial Non-Dilated Left Ventricular Cardiomyopathy. Clinical genetics 2026. link 26 Sahin AT, Keskin O, Kesriklioglu S, Moloshova N, Kan H, Kaleli MF et al.. Prevalence and clinical relevance of left septal fascicular block following conduction system pacing. Journal of electrocardiology 2026. link 27 Ko CJ, MacGibeny M, Choate K. Partial Spiky Acantholysis due to Loss of Desmosomal Attachments in Erythrokeratodermia Cardiomyopathy Syndrome. Journal of cutaneous pathology 2026. link 28 Xiao Q, Wang S, Gong Q, Zhao Z, Zhang L, Xiong F. Danon Disease Diagnosed by Multimodal Imaging: A Case Report. Journal of clinical ultrasound : JCU 2026. link 29 Sarmiento-Ortega VE, Moroni-González D, Avelino-Cruz JE, Garcia-Gonzalez M, Vázquez-Roque R, Brambila E et al.. Pioglitazone attenuates cardiovascular remodeling cadmium-induced through the MAPK pathway. Toxicology and applied pharmacology 2026. link 30 Radenkovic S, Preston G, Budhraja R, Muffels I, Ligezka A, Staff NP et al.. PGM1 deficiency is linked to sarcomeric and mitochondrial dysfunction in patient-derived iPSC-cardiomyocytes. Journal of translational medicine 2026. link 31 Zhao Y, Xu T, Ye C, Zhang K, Heng X, Huang S et al.. Lithospermic Acid Improves Doxorubicin-Induced Cardiomyopathy Through Sirtuin-3-Mediated Deacetylation of p53. Phytotherapy research : PTR 2026. link 32 Li W, Wang M, Ruan Z, Ren Y, Zhu L, Zhang B. SFRP4 Knockdown Attenuates Dsg2-Deficient Arrhythmogenic Cardiomyopathy by Down-Regulating TGF-β and Smad3. Biochemical genetics 2026. link 33 Tuvali O, Kuperstein R, Zwas DR, Volodarsky I, Vaisbuch E, Shimoni S et al.. Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy. JACC. Heart failure 2026. link 34 Yan Y, Xiang C, Wang X, Ran Y, Mou L, Wang L et al.. n-Butylphthalide alleviates obesity-induced cardiomyopathy by binding directly to Keap1. International immunopharmacology 2026. link 35 You J, Yang L, Qin Y, Tian C, Yang X, Xiang M et al.. Discovery and Structure-Activity Relationship Studies of Diazepine Derivatives as a New Class of Ferroptosis Inhibitors with Potent Efficacy in the Doxorubicin-Induced Cardiomyopathy Model. Journal of medicinal chemistry 2026. link 36 Kohno Y, Kawano H, Akashi R, Eguchi M, Matsuo T, Oku K et al.. Change in incidence of patients with peripartum cardiomyopathy. Hypertension research : official journal of the Japanese Society of Hypertension 2026. link 37 Wang M, Teng T, Mo D, Chen R, Xu J, Dong Z et al.. Neuroticism as a protective factor for cardiomyopathy: A mediation Mendelian randomization study. Journal of affective disorders 2026. link 38 Hao Y, An Z, Wang H, Gao J, He R, Ding Y et al.. Familial Frequent Premature Ventricular Contractions and the Relevance of Titin Mutations. Pacing and clinical electrophysiology : PACE 2026. link 39 Hussain MW, Malik MA. Peripartum cardiomyopathy presenting during caesarean section. BMJ case reports 2026. link 40 Yu Y, Wang X, Zhang J, Qian Z, Wang Y, Hou X et al.. The Risk Prediction Tool for Pacing-Induced Cardiomyopathy in Right Ventricular Pacing Patients. Pacing and clinical electrophysiology : PACE 2026. link 41 Liu N, Yang K, Cao G, Chen Z, Yin G, Dong W et al.. Sex-Specific Cardiac Magnetic Resonance Phenotypes in Danon Disease: A Retrospective Cohort Study. Journal of magnetic resonance imaging : JMRI 2026. link 42 Long Y, Xiao Y, Chen C, Peng C, Zhang Y. The effect of astragaloside IV on a model of isoproterenol-induced hypertrophic injury in H9c2 cells. Acta pharmaceutica (Zagreb, Croatia) 2026. link 43 Goyal G, Debnath A, Pal AK, Taleuzzaman M, Nagarajan K, Kumar V. In Silico, In Vitro, and In Vivo Evaluation of Woodfordia Fruticosa for Cardio Protection against Doxorubicin-Induced Cardiomyopathy. Chemistry & biodiversity 2026. link 44 Cheng H, Wang J, Ting W. The Therapeutic Targeting Effect of Toll-Like Receptors and Their Related Signaling Pathways in Cardiomyopathy. Immunological investigations 2026. link 45 Dubey N, Chaturvedi G, Panchbhai P, Singh S, Goyal A, Singh N et al.. From Defence to Dysfunction: The Dual Role of Autophagy and Mitophagy in Cardiomyopathy. Journal of biochemical and molecular toxicology 2026. link 46 Serban T, Müller T, Knecht S, Abid QU, Huang H, Subin B et al.. Prevalence of arrhythmia-induced cardiomyopathy: A systematic review and meta-analysis. Heart rhythm 2026. link 47 Suliman M, Altalbawy FMA, H M, Kazmi SW, Sharma A, Kumar MR et al.. Chemo-/radiotherapy-induced cardiomyopathy: roles of mitochondria and endoplasmic reticulum. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2026. link 48 Castrichini M, Ferreira Felix I, Karlinski Vizentin V, Garmany R, Huynh T, Haq IU et al.. Outcomes of Ventricular Tachycardia Ablation in Cardiac Laminopathy: An Updated Systematic Review and Single-Arm Meta-Analysis. Journal of cardiovascular electrophysiology 2026. link 49 Stabenau HF, Matos JD, Kramer DB, Sau A, Pastika L, Sieliwonczyk E et al.. The spatial ventricular gradient is a non-invasive, vectorcardiographic correlate of cardiac fibrosis. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2026. link 50 Cau R, Gatti M, Suri JS, D'Angelo T, Saba L. Clinical application of cardiac computed tomography in cardiomyopathy. The international journal of cardiovascular imaging 2026. link 51 van der Stuijt W, Friedman PA, Deshmukh AJ, Daly M, Downey R, Aasbo JD et al.. Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. Heart rhythm 2026. link 52 Chen G, Yao Y, Jiang Y, Qi H, Liu Y, Yin L et al.. Single-Cell Analyses Reveal IKKα Regulates the Interaction Between Macrophages and T Cells in the Doxorubicin-Induced Cardiomyopathy. Inflammation 2026. link 53 Chang Y, Rath EM, Soka M, Singer ES, Trivedi G, Burns C et al.. Increased yield of genetic diagnoses in inherited heart diseases using expanded genome and RNA-splicing analyses. Genetics in medicine : official journal of the American College of Medical Genetics 2026. link 54 Figueira F, de Sá Freitas Tavares M, Andreucci CB, Souto BGA, Osório NMS. Effectiveness of echocardiography and cardiac magnetic resonance for screening and monitoring cardiomyopathy in people living with HIV: a mixed-methods systematic review protocol. Systematic reviews 2026. link 55 Hyder SA, Shirwany H, Parcha V, Scheinuk JE, Saleh A, Sghayyer M et al.. Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study. The American journal of cardiology 2026. link 56 Hamzehlou S, Mortlock RD, Echeandia-Francis C, Zhou J, Xing C, Agim NG et al.. Erythrokeratodermia-Cardiomyopathy Syndrome: Expanding the DSP Mutational Spectrum Beyond Proline Substitutions. Pediatric dermatology 2026. link 57 Zhang W, Wang Z, Reid O, Harris F, Man K, Wang M et al.. Per- and Polyfluoroalkyl Substances Induce Cardiotoxicity and Alter Protein Profiles of Extracellular Matrix, Metabolism, and Mitochondrial Function in Human Cardiomyocytes. Chemical research in toxicology 2026. link 58 Lima BB, Kronenberg MW, Carr CM, Duran J, Chareonthaitawee P. How to prepare patients for fluorine-18 fluorodeoxyglucose positron emission tomography myocardial viability assessment. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2026. link 59 Ciccone MP, Panfili FM, Bacigalupo F, Brusco F, Florean L, Re F et al.. A Novel POPDC2 Pathogenic Variant in a Young Patient With Cardiac Conduction Disease and Hypertrophic Cardiomyopathy. Clinical genetics 2026. link 60 Liu R, Lu M, Liu Y, Li N, Yang J, Zhao F et al.. A lysosome-targetable fluorescent probe for monitoring peroxynitrite fluctuations and therapeutic evaluation in ferroptosis-induced cardiomyopathy. Talanta 2026. link 61 Puljevic M, Velagic V, Ivandic H, Hrabac P, Petrovic M, Pervan B. Time to rethink ICD indications in non-ishaemic cardiomyopathy? Evidence from a meta-analysis across therapeutic eras. ESC heart failure 2026. link 62 Ellis SG, Alencherry B, Ziada K, Tamis-Holland J, Whitehead E, Tang WHW. Predicting LVEF After PCI and its Effect on Clinical Outcomes in Patients With Stable Ischemic Cardiomyopathy and LVEF≤50. The American journal of cardiology 2026. link 63 Liao J, Zhou Z, Zhang Y, Miao Z, Li G, Xiao H et al.. Coronary Artery Bypass Grafting With or Without Concomitant Surgical Ventricular Reconstruction in Ischemic Cardiomyopathy Patients. Cardiovascular drugs and therapy 2026. link 64 Martini M, Brizzi LF, Pinci S, Rigato I, Corrado D, Pilichou K et al.. Phenotypic spectrum and prognostic stratification in desmoglein-2-associated arrhythmogenic cardiomyopathy: Results from a pooled analysis. Heart rhythm 2026. link 65 Nucifora G, Muser D, Bradley J, Tsoumani Z, De Angelis G, Caiffa T et al.. Unsupervised phenotypic clustering of cardiac MRI data reveals distinct subgroups associated with outcomes in ischemic cardiomyopathy. The international journal of cardiovascular imaging 2026. link 66 Vauhkonen PK, Kiiskilä JM, Hytönen S, Koskela R, Mäyränpää MI, Lindroos KM. Microscopic cardiac pathology in forensic autopsies: a comparative study of anabolic androgenic steroid users and non-users. International journal of legal medicine 2026. link 67 Tonko JB, Cabero-Vidal G, Ruipérez-Campillo S, Cabrera-Borrego E, Lozano C, Ramírez E et al.. Endo-epicardial electrical disarray in arrhythmogenic cardiomyopathy with ventricular arrhythmias. Heart rhythm 2026. link 68 Patel RK. BM3D filtering with Ensemble Hilbert-Huang Transform and spiking neural networks for cardiomegaly detection in chest radiographs. Computational biology and chemistry 2026. link 69 Zhang Q, Zhang M, Liu Y, Shi P, Qi H, Jiang M et al.. ULK1 activates NCOA4‑mediated ferritinophagy via the Beclin1/VPS34 complex in cardiomyocyte hypertrophy. Molecular medicine reports 2026. link 70 Patlolla SH, Crestanello JA, Schaff HV, Lahr BD, Lee AT, Anand V et al.. Changes in ejection fraction after coronary artery bypass grafting for ischemic cardiomyopathy: Impact on survival and determinants of improvement. The Journal of thoracic and cardiovascular surgery 2026. link 71 Bellisario I, Aimo A, Todiere G, Alderotti B, Gueli IA, Grigoratos C et al.. Dilated cardiomyopathy vs. non-dilated left ventricular dysfunction: genotype-phenotype relationship and outcome. International journal of cardiology 2026. link 72 Ren QX, Liu YJ, Wang P, Song X, Zhao Q, Cao YN et al.. miR-221 Mediates the Regulation of Phospholamban Expression and Cardiac Contractility by ZBTB20. Acta physiologica (Oxford, England) 2026. link 73 Abdaem J, Labib D, Beaudry R, Amakiri A, Dykstra S, Feng Y et al.. Patient-Specific Registration of Segmental Jeopardy and Viability: Novel Method to Guide Revascularization in Ischemic Cardiomyopathy. JACC. Cardiovascular imaging 2026. link 74 Bonanni F, Gueli IA, Bellisario I, Todiere G, Aimo A, Alderotti B et al.. European task force reclassification of dilated and non-dilated cardiomyopathies identifies a high arrhythmic-risk overlap phenotype. International journal of cardiology 2026. link 75 Hollander SA, Rosenthal D. Meeting report: Expanding access to advanced cardiac therapies, including ventricular assist devices (VADs) and heart transplantation in muscular dystrophy. Neuromuscular disorders : NMD 2026. link 76 Nagaraj G, Vellaichamy E. CNP inhibits T. Archives of biochemistry and biophysics 2026. link 77 Krittayaphong R, Songsangjinda T, Kaolawanich Y, Jirataiporn K, Yindeengam A. Prevalence and prognosis of non-dilated left ventricular cardiomyopathy in patients referred for cardiac magnetic resonance. European radiology 2026. link 78 Mannion J, Prendiville T, Murphy K, Galvin J. Regression of massive left ventricular hypertrophy in Danon disease. Acta cardiologica 2026. link 79 Heilein E, Kilian LS, Sossalla S, Meder B, Völkers M, Frese KS et al.. Strip1 Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy. Cells 2026. link 80 Han H, Luo T, Liu C, Ou W, Zhang Y, Zhang Z et al.. Vericiguat as a Novel Ferroptosis Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity. Basic & clinical pharmacology & toxicology 2026. link 81 Aldawsari KA, Kennedy KF, Herrada AM. Major Adverse Events of Cardiac Catheterization in Pediatric Cardiomyopathy: Insights From the IMPACT Registry. Journal of the American Heart Association 2026. link 82 Qin K, Li X, Wu X, Xie X, Xiang K, Zhou H et al.. AMPK-dependent maturation of hiPSC-derived cardiomyocytes induced by human cardiac fibroblast exosomes. Clinical and experimental hypertension (New York, N.Y. : 1993) 2026. link 83 ElSaygh J, Zaher A, Peterson SJ, Parikh MA, Frishman WH. Titin: The Missing Link in Cardiac Physiology. Cardiology in review 2026. link 84 Li J, Peng W, Kwok M, Ding H, Zhuo D, Gurung B et al.. Investigating PKD2 deficiency-associated cardiomyopathies using hESC-cardiomyocytes and bioengineered 3D ventricular cardiac tissue strips. Cell death & disease 2026. link 85 Kitano T, Nagata Y, Nabeshima Y, Dohi K, Takeuchi M. Prognostic value of right ventricular ejection fraction using three-dimensional echocardiography in patients with ischemic and dilated cardiomyopathy. Journal of echocardiography 2026. link 86 Sawasaki F, Sato A, Shimizu A, Matsumoto S, Kawamoto I, Murase M et al.. Suppression of the neutrophil-derived S100A8/A9 complex ameliorates doxorubicin-induced cardiomyopathy in non-human primates. Biochemical pharmacology 2026. link 87 Togashi D, Nakajima I, Sasaki K, Kasagawa A, Nakayama Y, Harada T et al.. Characteristics of Left Ventricular Endocardial Electroanatomic Voltage Mapping in Patients With Tachycardia-Induced Cardiomyopathy. Journal of cardiovascular electrophysiology 2026. link 88 Qiu H, Gladysheva IP. Therapeutic perspective on cardiomyopathy and heart failure in older adults through the lens of chronic inflammation. Vascular pharmacology 2026. link 89 Dhulkifle H, Therachiyil L, Hasan MH, Younis SM, Al-Shar'i NA, Yalcin HC et al.. PTUPB, a soluble epoxide hydrolase/cyclooxygenase‑2 dual inhibitor, reduces endothelial‑to‑mesenchymal transition and improves doxorubicin‑induced vascular and cardiac toxicity. Molecular medicine reports 2026. link 90 Huntelaar MJ, Hopman LHGA, van der Lingen ACJ, Rijnierse MT, Kemme MJB, Allaart CP et al.. Predictors of Atrial High-Rate Episodes and Inappropriate Device Therapy in Implantable Cardioverter Defibrillators. Pacing and clinical electrophysiology : PACE 2026. link 91 Král M, Švecová O, Jurák P, Halámek J, Šimurdová M, Šimurda J et al.. Field potential duration and its variability as essential parameters for revealing proarrhythmia: problematic aspects of analysis in cardiomyocytes derived from human pluripotent stem cells. Progress in biophysics and molecular biology 2026. link 92 Li C, Song Y, Cao B, Li J, Xu F, Du W et al.. Role of myocardium-derived exosomal miRNAs in doxorubicin-induced cardiomyopathy. Gene 2026. link 93 Yang Q, Zhao S, Zhao J, Shen Y, Hong Y, Qiu J et al.. Transplantation of Mitochondria isolated from iPSC-MSCs mitigates doxorubicin-induced cardiomyopathy by inhibiting cardiomyocyte senescence. Free radical biology & medicine 2026. link 94 Reventos-Presmanes J, Hernández-Romero I, Pellicer-Sendra B, Guillen-Buisan E, Serrano-Campaner J, Invers-Rubio E et al.. Noninvasive assessment of the ventricular arrhythmogenic substrate using electrocardiographic imaging during sinus rhythm: The NIAVAS study. Heart rhythm 2026. link 95 Wang D, Xu A, Su H, Zhang Y, Jiang L, Wang Y et al.. Sustained release of dual p38 inhibitors via supramolecular hydrogels to enhance cardiac repair after MI/R injury. Biomaterials 2026. link 96 Callon D, Hovhannisyan Y, Friob G, Vartanian-Grimaldi JS, Guennec BE, Lebreil AL et al.. Desmin mutations in cardiomyocytes increase susceptibility to coxsackievirus B3 infection by impairing antiviral IFN-β response and upregulating viral receptors expression. Stem cell research & therapy 2026. link 97 Marzook H, Dawuod OI, Mohammed AK, Karim A, Taneera J, Saleh MA et al.. GSK-3α activation mitigates Doxorubicin-induced cardiomyopathy through Keap1/Nrf2/HO-1 axis. Life sciences 2026. link 98 Hammoud A, Emerson P, Sasaki N, Chiang I, Mundisugih J, Tsurusaki S et al.. Advancing the current state of gene therapies using adeno-associated virus vectors to treat atrial cardiomyopathy. Expert opinion on drug delivery 2026. link 99 Hua Y, Chen H, Wu Y, Wu Y, Hu C, Zeng Y et al.. Injectable Magnolol-Peptide Hydrogel as a Minimally Invasive Treatment for Doxorubicin-Induced Cardiomyopathy via Inhibition of Aberrant Mitochondrial Fission. ACS applied materials & interfaces 2026. link 100 Meredith T, Picard MH, Churchill TW, Bernard S, Bertrand PB, Sanborn DMY et al.. State-of-the-Art in Echocardiographic Strain Imaging of Arrhythmogenic Cardiomyopathy. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2026. link

Original source

[1]
A large language model for complex cardiology care. — O'Sullivan JW, Palepu A, Saab K, Weng WH, Amponsah DK, Cheng E et al. Nature medicine (2026)
[2]
Rostafuroxin ameliorates cardiac glycoside-induced cardiomyocyte electrolyte imbalances and arrhythmia in ovo. — Rees J, Winkler A, Huettemeister J, Stengel L, Spangler P, Ramesh G et al. American journal of physiology. Heart and circulatory physiology (2026)
[3]
Precision cardiology: Integrating gene therapy, genome editing, and single-cell genomics. — Nishino T, Ono K Journal of cardiology (2026)
[4]
Inflammatory cardiomyopathy: Position paper of the Italian Society of Cardiology Working Group on cardiomyopathies and pericardial diseases in collaboration with the Italian Society of Cardiology Working Group on cardiac magnetic resonance. — Imazio M, Jahnsen V, Merlo M, Aimo A, Autore C, Barison A et al. International journal of cardiology (2026)
[5]
Genetic Mutations Underlying Growth Impairment and Cardiomyopathies in Children: Molecular Mechanisms, Clinical Implications and Targeted Therapies. — Dicorato MM, De Sario G, Carella MC, Guaricci AI, Ciccone MM, Forleo C et al. Genes (2026)
[6]
Inflammatory cardiomyopathy: an update for clinicians. — Imazio M Trends in cardiovascular medicine (2026)
[7]
Reconsidering a silent variant: SGCA's role in atypical cardiomyopathy. — Horowitz-Cederboim S, Hoffman-Lipschuetz R, Durst R, Shpitzen S, Shauer A, Zwas DR et al. European journal of human genetics : EJHG (2026)
[8]
Ventricular Assist Device Use in Pediatric Restrictive and Hypertrophic Cardiomyopathy: An ACTION Registry Analysis. — Mokshagundam D, Shezad MF, Conway J, Dykes J, Esteso P, Kobayashi R et al. ASAIO journal (American Society for Artificial Internal Organs : 1992) (2026)
[9]
When Substrate Meets Device: ICD Implantation and Therapy across the Spectrum of Cardiomyopathies. — Sisti N, Cardona A, Lazzari L, Fortuni F, Santoro A, Andreoli C et al. Pacing and clinical electrophysiology : PACE (2026)
[10]
Incidence, characteristics and long-term outcomes of peripartum cardiomyopathy: Insights from the Bergen peripartum cardiomyopathy study. — Kitsou V, Dingen H, Lunde T, Engan B, Macsali F, Saeed S Current problems in cardiology (2026)
[11]
Genotypic and phenotypic characterization of critical pediatric cardiomyopathy: A 20-patient cohort study. — Xu Y, Li M, Zhao X, Liang Y, Chai Y, Dai C et al. Clinica chimica acta; international journal of clinical chemistry (2026)
[12]
Genetic landscape of hereditary cardiomyopathies and arrhythmias in China. — Lu Y, Wang Z, Zhang S, Liu Y, Jin Y, Tian Z et al. Journal of genetics and genomics = Yi chuan xue bao (2026)
[13]
Arrhythmia-induced cardiomyopathy: focus on atrial fibrillation. — Fabritz L, Hatem SN, Sossalla S Nature reviews. Cardiology (2026)
[14]
Left Atrial Function in Pediatric Cardiomyopathies: A Multicenter Study. — Sabatino J, Avesani M, Moscatelli S, Castaldi B, Cattapan I, Sirico D et al. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2026)
[15]
Mechanism of lncRNA CYTOR/miR-24-3p in sevoflurane-mediated cardiomyocyte protection against hypoxia/reoxygenation injury in cardiomyocytes. — Liu Y, Feng X, Dai X, Li D, Luo Y Toxicology and applied pharmacology (2026)
[16]
Inflammation and Immunogenetics in Cardiomyopathies: From Molecular Mechanisms to Therapeutic Perspectives. — Peretto G, Villatore A, Cooper LT Immunological reviews (2026)
[17]
Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide-Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients. — Kawamura J, Ueno K, Nishikawa T, Takahashi Y, Nakae K, Okamoto Y Pediatric blood & cancer (2026)
[18]
Modeling heart rhythm using human engineered heart tissues. — Tu C, Caudal A, Liu Y, Narayan SM, Wu JC Nature protocols (2026)
[19]
Safety and Clinical Outcome of Subcutaneous Implantable Cardioverter-Defibrillators in an Asian Population: A Prospective Study. — Li KKY, Ching CK, Hussin A, Ngarmukos T, Chan JYS, Joung BY et al. Journal of cardiovascular electrophysiology (2026)
[20]
Impact of rhBNP and ivabradine on outcomes, cardiac markers, and microcirculation in ischemic heart failure. — Zhang L, Jiang Z, Ma H, Dong L, Feng S, Xu J et al. Heart & lung : the journal of critical care (2026)
[21]
Development of an artificial intelligence-based algorithm for the detection of left atrial enlargement from feline thoracic radiographs. — Valente C, Wodzinski M, Guglielmini C, Poser H, Zotti A, Mastromattei N et al. The veterinary quarterly (2026)
[22]
Acute arrhythmias in a long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency mouse model. — Elizondo G, Scalco A, Asal A, Chung H, Gaston G, Habecker BA et al. American journal of physiology. Heart and circulatory physiology (2026)
[23]
Effectiveness of upgrading to left bundle branch area pacing compared with biventricular pacing in patients with right ventricular pacing-induced cardiomyopathy. — He C, Xu S, Wang C, Li X, Zhu H, Zeng J et al. Heart rhythm (2026)
[24]
Cardiac CT fractal analysis of LV noncompaction and common cardiomyopathies. — Manohar A, Wong A, Castillo E, Gunderson A, Mistelbauer G, Bagherzadeh SP et al. Journal of cardiovascular computed tomography (2026)
[25]
A Novel SCN5A Missense Variant Associated With Familial Non-Dilated Left Ventricular Cardiomyopathy. — Castiglione V, Logiacco A, Barison A, Vittorini S, Botto N, Emdin M et al. Clinical genetics (2026)
[26]
Prevalence and clinical relevance of left septal fascicular block following conduction system pacing. — Sahin AT, Keskin O, Kesriklioglu S, Moloshova N, Kan H, Kaleli MF et al. Journal of electrocardiology (2026)
[27]
Partial Spiky Acantholysis due to Loss of Desmosomal Attachments in Erythrokeratodermia Cardiomyopathy Syndrome. — Ko CJ, MacGibeny M, Choate K Journal of cutaneous pathology (2026)
[28]
Danon Disease Diagnosed by Multimodal Imaging: A Case Report. — Xiao Q, Wang S, Gong Q, Zhao Z, Zhang L, Xiong F Journal of clinical ultrasound : JCU (2026)
[29]
Pioglitazone attenuates cardiovascular remodeling cadmium-induced through the MAPK pathway. — Sarmiento-Ortega VE, Moroni-González D, Avelino-Cruz JE, Garcia-Gonzalez M, Vázquez-Roque R, Brambila E et al. Toxicology and applied pharmacology (2026)
[30]
PGM1 deficiency is linked to sarcomeric and mitochondrial dysfunction in patient-derived iPSC-cardiomyocytes. — Radenkovic S, Preston G, Budhraja R, Muffels I, Ligezka A, Staff NP et al. Journal of translational medicine (2026)
[31]
Lithospermic Acid Improves Doxorubicin-Induced Cardiomyopathy Through Sirtuin-3-Mediated Deacetylation of p53. — Zhao Y, Xu T, Ye C, Zhang K, Heng X, Huang S et al. Phytotherapy research : PTR (2026)
[32]
SFRP4 Knockdown Attenuates Dsg2-Deficient Arrhythmogenic Cardiomyopathy by Down-Regulating TGF-β and Smad3. — Li W, Wang M, Ruan Z, Ren Y, Zhu L, Zhang B Biochemical genetics (2026)
[33]
Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy. — Tuvali O, Kuperstein R, Zwas DR, Volodarsky I, Vaisbuch E, Shimoni S et al. JACC. Heart failure (2026)
[34]
n-Butylphthalide alleviates obesity-induced cardiomyopathy by binding directly to Keap1. — Yan Y, Xiang C, Wang X, Ran Y, Mou L, Wang L et al. International immunopharmacology (2026)
[35]
Discovery and Structure-Activity Relationship Studies of Diazepine Derivatives as a New Class of Ferroptosis Inhibitors with Potent Efficacy in the Doxorubicin-Induced Cardiomyopathy Model. — You J, Yang L, Qin Y, Tian C, Yang X, Xiang M et al. Journal of medicinal chemistry (2026)
[36]
Change in incidence of patients with peripartum cardiomyopathy. — Kohno Y, Kawano H, Akashi R, Eguchi M, Matsuo T, Oku K et al. Hypertension research : official journal of the Japanese Society of Hypertension (2026)
[37]
Neuroticism as a protective factor for cardiomyopathy: A mediation Mendelian randomization study. — Wang M, Teng T, Mo D, Chen R, Xu J, Dong Z et al. Journal of affective disorders (2026)
[38]
Familial Frequent Premature Ventricular Contractions and the Relevance of Titin Mutations. — Hao Y, An Z, Wang H, Gao J, He R, Ding Y et al. Pacing and clinical electrophysiology : PACE (2026)
[39]
Peripartum cardiomyopathy presenting during caesarean section. — Hussain MW, Malik MA BMJ case reports (2026)
[40]
The Risk Prediction Tool for Pacing-Induced Cardiomyopathy in Right Ventricular Pacing Patients. — Yu Y, Wang X, Zhang J, Qian Z, Wang Y, Hou X et al. Pacing and clinical electrophysiology : PACE (2026)
[41]
Sex-Specific Cardiac Magnetic Resonance Phenotypes in Danon Disease: A Retrospective Cohort Study. — Liu N, Yang K, Cao G, Chen Z, Yin G, Dong W et al. Journal of magnetic resonance imaging : JMRI (2026)
[42]
The effect of astragaloside IV on a model of isoproterenol-induced hypertrophic injury in H9c2 cells. — Long Y, Xiao Y, Chen C, Peng C, Zhang Y Acta pharmaceutica (Zagreb, Croatia) (2026)
[43]
In Silico, In Vitro, and In Vivo Evaluation of Woodfordia Fruticosa for Cardio Protection against Doxorubicin-Induced Cardiomyopathy. — Goyal G, Debnath A, Pal AK, Taleuzzaman M, Nagarajan K, Kumar V Chemistry & biodiversity (2026)
[44]
The Therapeutic Targeting Effect of Toll-Like Receptors and Their Related Signaling Pathways in Cardiomyopathy. — Cheng H, Wang J, Ting W Immunological investigations (2026)
[45]
From Defence to Dysfunction: The Dual Role of Autophagy and Mitophagy in Cardiomyopathy. — Dubey N, Chaturvedi G, Panchbhai P, Singh S, Goyal A, Singh N et al. Journal of biochemical and molecular toxicology (2026)
[46]
Prevalence of arrhythmia-induced cardiomyopathy: A systematic review and meta-analysis. — Serban T, Müller T, Knecht S, Abid QU, Huang H, Subin B et al. Heart rhythm (2026)
[47]
Chemo-/radiotherapy-induced cardiomyopathy: roles of mitochondria and endoplasmic reticulum. — Suliman M, Altalbawy FMA, H M, Kazmi SW, Sharma A, Kumar MR et al. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2026)
[48]
Outcomes of Ventricular Tachycardia Ablation in Cardiac Laminopathy: An Updated Systematic Review and Single-Arm Meta-Analysis. — Castrichini M, Ferreira Felix I, Karlinski Vizentin V, Garmany R, Huynh T, Haq IU et al. Journal of cardiovascular electrophysiology (2026)
[49]
The spatial ventricular gradient is a non-invasive, vectorcardiographic correlate of cardiac fibrosis. — Stabenau HF, Matos JD, Kramer DB, Sau A, Pastika L, Sieliwonczyk E et al. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2026)
[50]
Clinical application of cardiac computed tomography in cardiomyopathy. — Cau R, Gatti M, Suri JS, D'Angelo T, Saba L The international journal of cardiovascular imaging (2026)
[51]
Acute results of the ASCEND EV study: A new modality of parasternal extravascular implantable cardioverter-defibrillator therapy including antitachycardia pacing. — van der Stuijt W, Friedman PA, Deshmukh AJ, Daly M, Downey R, Aasbo JD et al. Heart rhythm (2026)
[52]
Single-Cell Analyses Reveal IKKα Regulates the Interaction Between Macrophages and T Cells in the Doxorubicin-Induced Cardiomyopathy. — Chen G, Yao Y, Jiang Y, Qi H, Liu Y, Yin L et al. Inflammation (2026)
[53]
Increased yield of genetic diagnoses in inherited heart diseases using expanded genome and RNA-splicing analyses. — Chang Y, Rath EM, Soka M, Singer ES, Trivedi G, Burns C et al. Genetics in medicine : official journal of the American College of Medical Genetics (2026)
[54]
Effectiveness of echocardiography and cardiac magnetic resonance for screening and monitoring cardiomyopathy in people living with HIV: a mixed-methods systematic review protocol. — Figueira F, de Sá Freitas Tavares M, Andreucci CB, Souto BGA, Osório NMS Systematic reviews (2026)
[55]
Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study. — Hyder SA, Shirwany H, Parcha V, Scheinuk JE, Saleh A, Sghayyer M et al. The American journal of cardiology (2026)
[56]
Erythrokeratodermia-Cardiomyopathy Syndrome: Expanding the DSP Mutational Spectrum Beyond Proline Substitutions. — Hamzehlou S, Mortlock RD, Echeandia-Francis C, Zhou J, Xing C, Agim NG et al. Pediatric dermatology (2026)
[57]
Per- and Polyfluoroalkyl Substances Induce Cardiotoxicity and Alter Protein Profiles of Extracellular Matrix, Metabolism, and Mitochondrial Function in Human Cardiomyocytes. — Zhang W, Wang Z, Reid O, Harris F, Man K, Wang M et al. Chemical research in toxicology (2026)
[58]
How to prepare patients for fluorine-18 fluorodeoxyglucose positron emission tomography myocardial viability assessment. — Lima BB, Kronenberg MW, Carr CM, Duran J, Chareonthaitawee P Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology (2026)
[59]
A Novel POPDC2 Pathogenic Variant in a Young Patient With Cardiac Conduction Disease and Hypertrophic Cardiomyopathy. — Ciccone MP, Panfili FM, Bacigalupo F, Brusco F, Florean L, Re F et al. Clinical genetics (2026)
[60]
A lysosome-targetable fluorescent probe for monitoring peroxynitrite fluctuations and therapeutic evaluation in ferroptosis-induced cardiomyopathy. — Liu R, Lu M, Liu Y, Li N, Yang J, Zhao F et al. Talanta (2026)
[61]
Time to rethink ICD indications in non-ishaemic cardiomyopathy? Evidence from a meta-analysis across therapeutic eras. — Puljevic M, Velagic V, Ivandic H, Hrabac P, Petrovic M, Pervan B ESC heart failure (2026)
[62]
Predicting LVEF After PCI and its Effect on Clinical Outcomes in Patients With Stable Ischemic Cardiomyopathy and LVEF≤50. — Ellis SG, Alencherry B, Ziada K, Tamis-Holland J, Whitehead E, Tang WHW The American journal of cardiology (2026)
[63]
Coronary Artery Bypass Grafting With or Without Concomitant Surgical Ventricular Reconstruction in Ischemic Cardiomyopathy Patients. — Liao J, Zhou Z, Zhang Y, Miao Z, Li G, Xiao H et al. Cardiovascular drugs and therapy (2026)
[64]
Phenotypic spectrum and prognostic stratification in desmoglein-2-associated arrhythmogenic cardiomyopathy: Results from a pooled analysis. — Martini M, Brizzi LF, Pinci S, Rigato I, Corrado D, Pilichou K et al. Heart rhythm (2026)
[65]
Unsupervised phenotypic clustering of cardiac MRI data reveals distinct subgroups associated with outcomes in ischemic cardiomyopathy. — Nucifora G, Muser D, Bradley J, Tsoumani Z, De Angelis G, Caiffa T et al. The international journal of cardiovascular imaging (2026)
[66]
Microscopic cardiac pathology in forensic autopsies: a comparative study of anabolic androgenic steroid users and non-users. — Vauhkonen PK, Kiiskilä JM, Hytönen S, Koskela R, Mäyränpää MI, Lindroos KM International journal of legal medicine (2026)
[67]
Endo-epicardial electrical disarray in arrhythmogenic cardiomyopathy with ventricular arrhythmias. — Tonko JB, Cabero-Vidal G, Ruipérez-Campillo S, Cabrera-Borrego E, Lozano C, Ramírez E et al. Heart rhythm (2026)
[68]
BM3D filtering with Ensemble Hilbert-Huang Transform and spiking neural networks for cardiomegaly detection in chest radiographs. — Patel RK Computational biology and chemistry (2026)
[69]
ULK1 activates NCOA4‑mediated ferritinophagy via the Beclin1/VPS34 complex in cardiomyocyte hypertrophy. — Zhang Q, Zhang M, Liu Y, Shi P, Qi H, Jiang M et al. Molecular medicine reports (2026)
[70]
Changes in ejection fraction after coronary artery bypass grafting for ischemic cardiomyopathy: Impact on survival and determinants of improvement. — Patlolla SH, Crestanello JA, Schaff HV, Lahr BD, Lee AT, Anand V et al. The Journal of thoracic and cardiovascular surgery (2026)
[71]
Dilated cardiomyopathy vs. non-dilated left ventricular dysfunction: genotype-phenotype relationship and outcome. — Bellisario I, Aimo A, Todiere G, Alderotti B, Gueli IA, Grigoratos C et al. International journal of cardiology (2026)
[72]
miR-221 Mediates the Regulation of Phospholamban Expression and Cardiac Contractility by ZBTB20. — Ren QX, Liu YJ, Wang P, Song X, Zhao Q, Cao YN et al. Acta physiologica (Oxford, England) (2026)
[73]
Patient-Specific Registration of Segmental Jeopardy and Viability: Novel Method to Guide Revascularization in Ischemic Cardiomyopathy. — Abdaem J, Labib D, Beaudry R, Amakiri A, Dykstra S, Feng Y et al. JACC. Cardiovascular imaging (2026)
[74]
European task force reclassification of dilated and non-dilated cardiomyopathies identifies a high arrhythmic-risk overlap phenotype. — Bonanni F, Gueli IA, Bellisario I, Todiere G, Aimo A, Alderotti B et al. International journal of cardiology (2026)
[75]
Meeting report: Expanding access to advanced cardiac therapies, including ventricular assist devices (VADs) and heart transplantation in muscular dystrophy. — Hollander SA, Rosenthal D Neuromuscular disorders : NMD (2026)
[76]
CNP inhibits T — Nagaraj G, Vellaichamy E Archives of biochemistry and biophysics (2026)
[77]
Prevalence and prognosis of non-dilated left ventricular cardiomyopathy in patients referred for cardiac magnetic resonance. — Krittayaphong R, Songsangjinda T, Kaolawanich Y, Jirataiporn K, Yindeengam A European radiology (2026)
[78]
Regression of massive left ventricular hypertrophy in Danon disease. — Mannion J, Prendiville T, Murphy K, Galvin J Acta cardiologica (2026)
[79]
Strip1 Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy. — Heilein E, Kilian LS, Sossalla S, Meder B, Völkers M, Frese KS et al. Cells (2026)
[80]
Vericiguat as a Novel Ferroptosis Inhibitor Alleviates Doxorubicin-Induced Cardiotoxicity. — Han H, Luo T, Liu C, Ou W, Zhang Y, Zhang Z et al. Basic & clinical pharmacology & toxicology (2026)
[81]
Major Adverse Events of Cardiac Catheterization in Pediatric Cardiomyopathy: Insights From the IMPACT Registry. — Aldawsari KA, Kennedy KF, Herrada AM Journal of the American Heart Association (2026)
[82]
AMPK-dependent maturation of hiPSC-derived cardiomyocytes induced by human cardiac fibroblast exosomes. — Qin K, Li X, Wu X, Xie X, Xiang K, Zhou H et al. Clinical and experimental hypertension (New York, N.Y. : 1993) (2026)
[83]
Titin: The Missing Link in Cardiac Physiology. — ElSaygh J, Zaher A, Peterson SJ, Parikh MA, Frishman WH Cardiology in review (2026)
[84]
Investigating PKD2 deficiency-associated cardiomyopathies using hESC-cardiomyocytes and bioengineered 3D ventricular cardiac tissue strips. — Li J, Peng W, Kwok M, Ding H, Zhuo D, Gurung B et al. Cell death & disease (2026)
[85]
Prognostic value of right ventricular ejection fraction using three-dimensional echocardiography in patients with ischemic and dilated cardiomyopathy. — Kitano T, Nagata Y, Nabeshima Y, Dohi K, Takeuchi M Journal of echocardiography (2026)
[86]
Suppression of the neutrophil-derived S100A8/A9 complex ameliorates doxorubicin-induced cardiomyopathy in non-human primates. — Sawasaki F, Sato A, Shimizu A, Matsumoto S, Kawamoto I, Murase M et al. Biochemical pharmacology (2026)
[87]
Characteristics of Left Ventricular Endocardial Electroanatomic Voltage Mapping in Patients With Tachycardia-Induced Cardiomyopathy. — Togashi D, Nakajima I, Sasaki K, Kasagawa A, Nakayama Y, Harada T et al. Journal of cardiovascular electrophysiology (2026)
[88]
Therapeutic perspective on cardiomyopathy and heart failure in older adults through the lens of chronic inflammation. — Qiu H, Gladysheva IP Vascular pharmacology (2026)
[89]
PTUPB, a soluble epoxide hydrolase/cyclooxygenase‑2 dual inhibitor, reduces endothelial‑to‑mesenchymal transition and improves doxorubicin‑induced vascular and cardiac toxicity. — Dhulkifle H, Therachiyil L, Hasan MH, Younis SM, Al-Shar'i NA, Yalcin HC et al. Molecular medicine reports (2026)
[90]
Predictors of Atrial High-Rate Episodes and Inappropriate Device Therapy in Implantable Cardioverter Defibrillators. — Huntelaar MJ, Hopman LHGA, van der Lingen ACJ, Rijnierse MT, Kemme MJB, Allaart CP et al. Pacing and clinical electrophysiology : PACE (2026)
[91]
Field potential duration and its variability as essential parameters for revealing proarrhythmia: problematic aspects of analysis in cardiomyocytes derived from human pluripotent stem cells. — Král M, Švecová O, Jurák P, Halámek J, Šimurdová M, Šimurda J et al. Progress in biophysics and molecular biology (2026)
[92]
Role of myocardium-derived exosomal miRNAs in doxorubicin-induced cardiomyopathy. — Li C, Song Y, Cao B, Li J, Xu F, Du W et al. Gene (2026)
[93]
Transplantation of Mitochondria isolated from iPSC-MSCs mitigates doxorubicin-induced cardiomyopathy by inhibiting cardiomyocyte senescence. — Yang Q, Zhao S, Zhao J, Shen Y, Hong Y, Qiu J et al. Free radical biology & medicine (2026)
[94]
Noninvasive assessment of the ventricular arrhythmogenic substrate using electrocardiographic imaging during sinus rhythm: The NIAVAS study. — Reventos-Presmanes J, Hernández-Romero I, Pellicer-Sendra B, Guillen-Buisan E, Serrano-Campaner J, Invers-Rubio E et al. Heart rhythm (2026)
[95]
Sustained release of dual p38 inhibitors via supramolecular hydrogels to enhance cardiac repair after MI/R injury. — Wang D, Xu A, Su H, Zhang Y, Jiang L, Wang Y et al. Biomaterials (2026)
[96]
Desmin mutations in cardiomyocytes increase susceptibility to coxsackievirus B3 infection by impairing antiviral IFN-β response and upregulating viral receptors expression. — Callon D, Hovhannisyan Y, Friob G, Vartanian-Grimaldi JS, Guennec BE, Lebreil AL et al. Stem cell research & therapy (2026)
[97]
GSK-3α activation mitigates Doxorubicin-induced cardiomyopathy through Keap1/Nrf2/HO-1 axis. — Marzook H, Dawuod OI, Mohammed AK, Karim A, Taneera J, Saleh MA et al. Life sciences (2026)
[98]
Advancing the current state of gene therapies using adeno-associated virus vectors to treat atrial cardiomyopathy. — Hammoud A, Emerson P, Sasaki N, Chiang I, Mundisugih J, Tsurusaki S et al. Expert opinion on drug delivery (2026)
[99]
Injectable Magnolol-Peptide Hydrogel as a Minimally Invasive Treatment for Doxorubicin-Induced Cardiomyopathy via Inhibition of Aberrant Mitochondrial Fission. — Hua Y, Chen H, Wu Y, Wu Y, Hu C, Zeng Y et al. ACS applied materials & interfaces (2026)
[100]
State-of-the-Art in Echocardiographic Strain Imaging of Arrhythmogenic Cardiomyopathy. — Meredith T, Picard MH, Churchill TW, Bernard S, Bertrand PB, Sanborn DMY et al. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2026)

Share:Twitter Reddit LinkedIn